车床
发表于 2025-3-25 06:05:24
http://reply.papertrans.cn/23/2250/224942/224942_21.png
CYT
发表于 2025-3-25 11:32:34
http://reply.papertrans.cn/23/2250/224942/224942_22.png
准则
发表于 2025-3-25 13:26:57
http://reply.papertrans.cn/23/2250/224942/224942_23.png
decipher
发表于 2025-3-25 16:21:45
Biochemical and Biological Characterization of NAP-1/ IL-8-Related Cytokines in Lesional Psoriatic nsisting of polymorphonuclear leukocytes (PMN) (1). The absence of bacteria as the cause of PMN infiltration led to the hypothesis that endogenous chemoattractants located in the epidermal cell layer of psoriatic plaques may attract PMN into the inflammatory focus.
nerve-sparing
发表于 2025-3-25 20:35:17
http://reply.papertrans.cn/23/2250/224942/224942_25.png
四溢
发表于 2025-3-26 01:50:00
0065-2598 groups of a peptide consisting of 72 amino acids which was a potent activator of neutrophils and a chemotactic agent for lymphocytes. The first symposium of this series was held at the Royal College of Surgeons of England in December 1988, entitled Novel Neutrophil Stimulating Peptides, and brought
Intercept
发表于 2025-3-26 04:24:53
http://reply.papertrans.cn/23/2250/224942/224942_27.png
expire
发表于 2025-3-26 08:35:19
http://reply.papertrans.cn/23/2250/224942/224942_28.png
认为
发表于 2025-3-26 12:58:43
Activation of Human Neutrophils by NAP-1 and Other Chemotactic Agonists,ent in the interstitium are complex events involving motile and secretory functions. Three main responses of neutrophils, the shape change, the exocytosis of storage components, and the respiratory burst can be analyzed in real time ., and we shall describe here how these responses are induced by NAP-1 and other chemotactic agonists.
冥界三河
发表于 2025-3-26 17:36:34
GRO: A Novel Chemotactic Cytokine,ory functions in growth and differentiation as well. Our studies with the GRO gene represent one of the first to describe a novel cytokine expressed by fibroblasts and epithelial cells as well as cells of the immune system, with regulatory functions both in growth and in the inflammatory response (1, 2, 3).